At present, drugs in terms of ApoE4 quantity and lipidation are mainly agonists of liver X receptor (LXR) and retinol X receptor (RXR)-Bexarotene is approved for the treatment of cutaneous T-cell lymphoma and can be reused for other indications. Here, APOE is linked to primary cutaneous T-cell non-Hodgkin lymphoma.